辛伐他汀对冠心病患者新发心房颤动的预防作用

目的：探讨辛伐他汀对冠心病患者新发心房颤动（房颤）的预防作用。方法：选取住院治疗的冠心病患者为研究对象,将322例冠心病患者随机分为两组,辛伐他汀组（164例）给予辛伐他汀10 mg治疗,对照组（158例）给予常规治疗,观察两组患者治疗前后血清超敏C反应蛋白（hs-CRP）的变化,随访统计新发房颤发生率。结果：治疗后两组血清hs-CRP水平均较治疗前降低,辛伐他汀组降低更明显,由（6.43±1.70）mg/L降至（3.98±1.52）mg/L,两组差异有统计学意义（P〈0.05）;入选的322例患者中,54例患者发生房颤,其中,辛伐他汀组8例（4.9%）,对照组46例（29%）,辛伐他汀组房颤发生率明显低于对照组,两组差异有统计学意义（P〈0.05）。结论：辛伐他汀能明显降低冠心病患者房颤的发生率。

Prevention of new occurred atrial fibrillation in coronary heart disease patients by Simvastatin

Objective： To evaluate the effect of Simvastatin on prevention of new occurred atrial fibrillation（AF） in coronary heart disease patients.Methods： 322 patients with coronary heart disease（CHD） were randomly divided into two groups,Simvastatin group（164 cases） was given Simvastatin 10 mg and the control group（158 cases） was given routine treatment,changes of levels of high sensitive C-reactive protein in two groups were observed before and after treatment.The incidence rates of AF were measured in following-up.Results： The level of hs-CRP decreased after treatment in two groups,Simvastatin group decreased more obvious（P0.05）.54 cases of the 322 patients developed AF during follow-up,8 case（4.9%） in the Simvastatin group and 46 cases（29%） in the control group,the incidence of AF in the Simvastatin group was significantly less than the control group（P0.05）.Conclusion： Simvastatin can reduce the incidence of AF obviously in coronary heart disease patients.